2009, Number 1
<< Back Next >>
Rev Mex Oftalmol 2009; 83 (1)
Bevacizumab (Avastin) intravítreo en edema macular secundario a oclusión de vena central de la retina
Levine-Berebichez A, Celis-Suazo B, Rojas-Juárez S, García-Franco R,Quezada-Torres E, Ramírez-Estudillo JA, Aguirre-González AF, Rojas-Díaz J, Peñaflor-Siller J
Language: Spanish
References: 23
Page: 18-25
PDF size: 360.56 Kb.
ABSTRACT
Objective: To determine the evolution of macular edema secondary to occlusion of the central vein of the retina after the intravitreous application of bevacizumab.
Material and methods: A prospective, experimental, longitudinal study was made of series of cases.
Results: 23 eyes were injected. The average age was 65 years. The average macular thickness before treatment was 649 µ, the major reduction of thickness after one month of treatment was 308 µ, was observed regression in the thickness to spot getting to be equal at the thickness before treatment to the 4 months of pursuit registering itself a thickness to spot of 640 µ. 65% of the patients presented/displayed edema to spot recidive, 40% of the patients received one second dose. In the group of portrayed patients the average of the thickness spot before the second application was of 571µ with a mayor reduction of the thickness spot to the month after the second application with an average of 257µ.
Conclusions: The use of intravitreous Bevacizumab favors the diminution of macular edema to spot secondary to occlusion of the central vein of the retina being supposed a temporary stabilization in the function of the hematoretinal barrier.
REFERENCES
Opremcak EM, Bruce RA, Lomeo MD, Ridenour CD, Letson AD, Rehmar AJ. Radial optic neurotomy for central retinal vein occlusion. A retrospective pilot study of 11 consecutive cases. Retina 2001; 21:408-415.
The central vein occlusion study group. Baseline and early natural history report: The central vein occlusion study. Arch Ophthalmol 1993; 111:1087-1095.
Mirshahi A, Roohipoor R, Lashay A, Mohammadi SF, Mansouri MR. Surgical induction of chorioretinal venus anastomosis in ischaemic central vein occlusion: a non-randomised controlled clinical trial. Br J Ophthalmol 2005; 89:64-69.
Zegarra H, Gutman FA, Conforto J. The natural course of central retinal vein occlusion. Ophthalmology 1979; 86:1931-42.
Ratz EZ, Frank RN, Shin DH, Kim C. Risk factors for retinal vein occlusions: a case controlled study. Ophthalmology 1992; 99:509-514.
The central vein occlusion study group M report. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology 1995; 102:1425-1433.
Green WR, Chan CC, Hutchins GM, Terry JM. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc 1981; 79:371-422.
Hayreh SS. Pathogenesis of occlusion of the central retinal vessels. Am J Ophthalmol 1971; 72:998-1011.
Haureh SS. Classification of central retinal vein occlusion. Ophthalmology 1983; 90:458-474.
The central vein occlusion study group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997; 115:486-491.
Leonard BC, Coupland SG, Kertes PJ, Bate R. Long-term follow- up of a modified technique for laser-induced chorioretinal venus anastomosis in nonisquemic central retinal vein occlusion. Ophthalmology 2003; 110:948-954.
Witmer AN, Vrensen GF, Van Noorden CJ, Schlingermann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003; 22:1-29.
Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146:1029-1039.
Midgley R, Kerr D. Bevacizumab: current status and future directions. Ann Oncol 2005; 16:999-1004.
Michels S, Rosenfeld PJ, Puliafito CA y cols. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-weeks results of an uncontrolled openlabel clinical study. Ophthalmology 2005; 112:1035-1047.
Avastin Prescribing Information. Genetch Inc. December 2004.
Jain RK. Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7:987-989.
Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36:331-335.
Rosenfeld PJ. Avastin for AMD Program and abstracts of the Subespeciality Day Retina, American Academy of Ophthalmology; October 14-15, 2005; Chicago, Illinois.
Aiello LP, Avery RL, Arrigg PG y cols. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331:1480–1487.
Pe’er J, Shweiki D, Itin A y cols. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995; 72:638–645.
Pe’er J, Folberg R, Itin A y cols. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 1998; 105:412–416.
Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA y cols. Intravitreal Bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion. A Short-Term Study. Retina, March 2006.